![](https://medcitynews.com/uploads/2021/07/GettyImages-1280895783-150x150.jpg)
blood cancer
-
FDA Approves GSK Myelofibrosis Med That Has Edge Over Others in Drug Class
FDA approval of GSK’s Ojjaara in myelofibrosis introduces a new competitor to blockbuster Incyte drug Jakafi. Ojjaara was part of GSK’s $1.9 billion acquisition of Sierra Oncology last year.
-
Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal
Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech’s commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
FDA approves PharmaEssentia interferon drug for a rare type of blood cancer
Polycythemia vera, a rare blood cancer characterized by the overproduction of red blood cells, now has its first FDA-approved drug treatment. The agency awarded the regulatory nod to a PharmaEssentia drug that reduces the levels of those blood cells.
-
Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
-
Italy’s Menarini Group to acquire Stemline Therapeutics for $677M
New York-based Stemline won Food and Drug Administration approval in December 2018 for Elzonris, a drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN, an extremely rare but aggressive form of leukemia.
-
Novo Nordisk, bluebird bio partner on genome editing in hemophilia
The companies will use Novo Nordisk’s experience with hemophilia and bluebird’s TALENs-based genome editing technology, megaTAL, with a particular focus on hemophilia A.
-
Startups, Artificial Intelligence, BioPharma
Personalized cancer treatment startup Notable Labs nabs $40M Series B
Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company’s technology and growth of its commercial use cases.
-
Oncopeptides looks forward to updates on myeloma drug at European hematology conference
In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.
-
2018 ASH meeting to feature new CAR-T therapies for myeloma
Bispecific antibodies like Amgen’s AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies – which target the same antigen – be possible?
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.